Eva De Backer

Dr. Eva De Backer

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Gastroenterology
Verified
Journal Article
Closed access
EBEva De Backer
Eva De Backer
HBHannelore Bode
Hannelore Bode
FBFilip Baert
Filip Baert

29 December 2017 in Acta Clinica Belgica
Verified
Journal Article
Closed access
EBEva De Backer
Eva De Backer
FGFélix Gremonprez
Félix Gremonprez
GBGuy Brusselle
Guy Brusselle
PDPieter Depuydt
Pieter Depuydt
JDJo Van Dorpe
Jo Van Dorpe
EDEric Derom
Eric Derom
We present a case of a 55-year-old Caucasian male with manifestations of dermatomyositis complicated with rapidly progressive interstitial lung disease (RP-ILD). Diagnosis of anti-MDA5 positive dermatomyositis was made. Myositis specific antibodies (MSA) can be used for diagnosis and predicting prognosis in patients with polymyositis and dermatomyositis. Anti-MDA5 positive dermatomyositis should be considered in patients presenting with dermatomyositis and a disease course resembling antisynthetase syndrome in the absence of antisynthetase autoantibodies, especially if a remarkably high ferritin is noted. Anti-MDA5 autoantibodies have been associated with RP-ILD and adverse outcome. In patients with anti-MDA5 autoantibodies, early diagnosis and aggressive immunosuppressive treatment may improve prognosis. This case highlights the importance of determining MSA in patients with dermatomyositis and associated interstitial lung disease, as this has implications for diagnosis, prognosis and therapy.

9 January 2018 in Acta Clinica Belgica
Verified
Journal Article
Closed access
EBEva De Backer
Eva De Backer
HHHeidi Hannon
Heidi Hannon
(2018). Flucloxacillin-induced hypokalaemia: a case report. Acta Clinica Belgica. Ahead of Print.

2 January 2022 in Acta Clinica Belgica
Verified
Journal Article
Closed access
EBEva De Backer
Eva De Backer
DDDries Deeren
Dries Deeren
Background Hyperproliferative crises with hyperleukocytosis occur frequently in the disease course of refractory or relapsed acute myeloid leukemia (AML). Palliative cytoreduction aims to control blast count in order to avoid life-threatening complications and preserve quality of life in patients unfit for intensive treatment. In our center, low-dose intravenous melphalan is sometimes used with this intent.Methods: We performed a retrospective analysis of patients with AML who were treated with low-dose intravenous melphalan (15-30 mg/m(2)) in a palliative setting.Results: Thirty patients with AML who received low-dose melphalan (15-25 mg/m(2)) were identified. In total, 63 administrations of low-dose melphalan were counted. A clear cytoreductive effect (>50%) was seen within a few days in 78% of melphalan administrations. The median duration of response after an individual dose was 17 days (interquartile range [IQR] 10-26). The median overall survival was 29 days (IQR 16-73). Most common side effects were worsening pancytopenia with neutropenic fever and an increase in transfusion dependency and tumor lysis syndrome.Conclusion: Intravenous low-dose melphalan is effective, quick and safe as palliative cytoreductive therapy in patients with hyperproliferative AML. It can be considered in palliative care of patients refractory to prior treatment with preserving acceptable quality of life. Our small retrospective cohort is the first to report the use of low-dose intravenous melphalan as palliative cytoreductive treatment in this population.

7 September 2026 in Acta Clinica Belgica
Verified
Journal Article
Closed access
EIElias Iturrospe
Elias Iturrospe
EBEva De Backer
Eva De Backer
MMMarie-Berthe Maes
Marie-Berthe Maes
KDKathleen Deiteren
Kathleen Deiteren
RFReinoud Flies
Reinoud Flies
CHCatharina van der Heijden
Catharina van der Heijden
We report the case of a patient with a de novo pathogenic germline variant causing GATA2 deficiency. GATA2 deficiency is a rare autosomal dominant inborn error of immunity caused by heterozygous lo...

29 June 2026 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
EBEva De Backer
Eva De Backer
FOFlorian Van Oers
Florian Van Oers
ZBZwi Berneman
Zwi Berneman
SASébastien Anguille
Sébastien Anguille
Acute myeloid leukemia (AML) is a heterogeneous and aggressive malignancy with limited therapeutic options and high relapse rates. Despite advances in genomic profiling, many genetic aberrations remain untargetable, and current risk stratification models often fail to predict treatment responses. Proteomics offers a complementary approach by directly measuring protein abundance, post-translational modifications, and protein–protein interactions, providing mechanistic insights into drug resistance, disease progression, and therapeutic vulnerabilities. In this review, we explore the emerging role of proteomics in AML, focusing on its application in biomarker discovery, prediction of drug responses, and identification of novel therapeutic targets. Special attention is given to antigen discovery for immunotherapy, where surface and immunopeptidomics enable the identification of AML-specific antigens and neoepitopes. These insights are critical for the development of antigen-targeted therapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR)-based immunotherapies. Integrating proteomics into a multiomics framework could provide actionable insights for guiding precision medicine and improving AML outcomes.